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Background: Femoral neck fractures are a common occurrence in patients suffering from osteoporosis, while
intracapsular hip fracture is rare in cases of osteoarthritis of the hip. Previous histomorphometric studies have
emphasized the association between bone microarchitecture and the risk of low-impact fractures in osteoarthritis
and osteoporosis patients. However, the strength of bone material is also a function of composition of organic
bone matrix. In order to compare tissue material properties in these two clinical conditions, serum and bone
pentosidine, a non-enzymatic collagen crosslinking element, was measured in patients who suffered a low-impact
fracture, and in patients with advanced osteoarthritis.
Methods: The patient population consisted of 70 patients who underwent hemiarthroplasty surgery for a femoral
neck fracture, and 41 patients with advanced hip joint osteoarthritis without a history of low- impact fracture, who
were indicated for total hip joint replacement. Pentosidine content was analyzed in bone samples and in serum
obtained from fracture and osteoarthritis patients using high performance liquid chromatography.
Results: Serum and bone concentrations of pentosidine were higher in subjects with hip fractures compared with
osteoarthritis after adjustment for age, sex, weight, serum creatinine, and diabetes. A significant positive correlation
was found between bone and serum pentosidine in fractured cases. A comparable relationship was also
demonstrated for pentosidine levels in serum and bone relative to differentiation of fracture and osteoarthritis
cases.
Conclusions: Serum pentosidine can be considered a potential biomarker for identification of subjects with
impaired bone quality and bone strength.
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The strength of bone material is a function of bone
microarchitecture, and tissue material properties. At the
material level, bone strength is determined by the degree
of mineralization of basic structural units, micro-
damage accumulation, and properties of the organic
bone matrix, namely collagen cross-link formation [1, 2].
These are regulated by cellular activities and tissue turn-
over rate [3]. Impaired enzymatic cross-linking and/or
increases in non-enzymatic cross-links in bone collagen* Correspondence: stepan@revma.cz
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mechanical properties in aging, involutional osteopor-
osis, and diabetes mellitus [4, 5]. Reduced bone turnover
allows the formation of additional collagen crosslinks by
non-enzymatic means, resulting in accumulation of non-
enzymatic advanced glycation end-products (AGEs) in
bone tissue [6, 7]. Bone collagen glycation allows micro-
damage in bone to spread more easily, therefore increas-
ing the total crack surface density, making bone tissue
more brittle and more likely to fracture [8, 9].
Out of several AGE crosslinks, pentosidine (PEN) has
been quantified in bone [10], and its accumulation has
been associated with the age-related degradation of bone
mechanical properties [11, 12]. PEN is a senescentle is distributed under the terms of the Creative Commons Attribution 4.0
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interaction between arginine and lysine amino acids and
free sugars [13, 14]. PEN has been shown to accumulate
with age in cortical bone of human femurs [15]. Accumu-
lation of AGEs in bone collagen matrix has been associ-
ated with brittleness of collagen fibers and impairment of
the mechanical properties of cortical and trabecular bone
[11, 12, 16, 17]. Increased content of PEN in cortical and
trabecular bone was associated with impairment of bone
quality in osteoporotic patients with hip fractures [18],
while plasma PEN levels were not increased in patients
with osteoarthritis compared with controls [19]. However,
serum and bone PEN has not been compared previously
in patients with hip osteoarthritis and low-impact hip
fractures.
To examine the performance of PEN as a biomarker
of impaired quality of organic bone matrix, potentially
associated with fracture risks, we compared PEN levels
in serum and proximal femoral bone specimens using
high performance liquid chromatography (HPLC) in
subjects who had undergone hemiarthroplasty for an
intracapsular hip fracture and from a group of fracture-
free patients with hip joint osteoarthritis.
Methods
Study participants
This cohort study was performed in patients followed as
part of routine care in the Department of Orthopedics,
Bulovka Hospital, Prague, Czech Republic. Serum and
femoral head bone specimens were collected from 70
subjects who had undergone hemiarthroplasty for an
intracapsular hip fracture. Simultaneously, bone speci-
mens from the iliac crest were obtained in random from
21 patients. The group with hip joint osteoarthritis,Table 1 Characteristics of the study population
Male
Fracture C
Number of subjects 21 2
Age (years) 77.3 ± 9,1a 6
Height (cm) 174.0 ± 7.0 1
Weight (kg) 75.9 ± 15.0 b 8
Prevalent fracture (No.) 2 0
Glucocorticoids (No.) 1 0
Smoking (No.) 2 2
Diabetes (No.) 3 6
Creatinine (μmol/l) 107 ± 33.9 9
Bone pentosidine (nmol/g dry bone mass) c 2.96 a 1
0.55;6.80 0
Serum pentosidine (nmol/l) c 73.6 a 2
48.4; 417.4 1
a:p < 0.001; b:p < 0.005; c:Median a 95 % CIwhich was without a history of low energy fractures, in-
cluded 41 patients in advanced stages of hip osteoarth-
ritis, who were indicated for total hip joint replacement,
63 % of the atrophic type, 24 % of the hypertrophic type
[20]. A complete clinical history, including details of spe-
cific common medical conditions (e.g., hypertension,
congestive heart failure, heart attack, and stroke, dia-
betes mellitus), lifestyle risk factors including smoking
(current, past, never) and alcohol consumption, detailed
personal history of glucocorticoids use (previous or on-
going), fracture history (type and trauma), and physical
examination were assessed. Excluded were patients with
Paget’s disease of the bone, malignancy, renal osteodystro-
phy, hyperparathyroidism, active liver disease or clinical
jaundice, previous treatment with aminobisphosphonates,
denosumab, teriparatide, vitamin D >50,000 IU/week or
active vitamin D analogs. Characteristics of the study sub-
jects are shown in Table 1.
Preparation of samples
Bone specimens obtained from the femoral head of fem-
oral neck fracture patients and specimens from the fem-
oral head of patients undergoing total hip replacement
for hip joint osteoarthritis were obtained from the cen-
tral part of the femoral head using a trephine, along the
femoral neck axis. The samples were taken more than
5 mm away from the osteotomy plane of the total hip
arthroplasty to avoid heat damage to the bone specimen.
In addition to bone from femoral heads, full thickness
bone specimens from the anterior ilium were harvested
2 cm posterior and 2 cm inferior to the anterior superior
iliac spine from 21 patients with hip fractures, using a
Rochester Bone Biopsy Trephine. The bone was cleaned
of adhering soft tissues and marrow. Bone specimensFemale
ontrols Osteoarthritis Fracture Controls Osteoarthritis
5 49 15
4.3 ± 10.9 77.3 ± 11.0 68.0 ± 7.9
76.0 ± 5.1 161.9 ± 6.9 162.9 ± 7.5





7.6 ± 21.7 90.9 ± 29.1 79.6 ± 9.1
.10 2.57 a 0.93
.41;2.41 0.75;5.11 0.45;1.98
7.1 71.5 a 30.3
5.46;80.3 31.4;154.6 16.2;108.0
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SpeedVac vacuum evaporator. The specimens of dry
bone (10 mg) were then hydrolyzed in 2 ml of 6 M
hydrochloric acid at 105 °C for 16 h. Collected blood
serum samples were stored at −20 °C until analysis.Pentosidine assay
Pentosidine was determined by reversed phase HPLC
combined with sensitive fluorescent detection, as pub-
lished previously [21]. Briefly, serum samples were
mixed with equal amounts of 35 % HCl and hydrolyzed
for 16 h at 105 °C. The bone samples were treated as
above. In the next step, the hydrolysate was purified and
pre-concentrated using solid phase extraction; the hy-
drolysate was mixed with a suspension of cellulose and
combined with a solution containing n-butyl alcohol and
acetic acid. This mixture was then applied to a purifica-
tion column filled with cellulose. The PEN-containing
fraction was then desorbed using 0.05 mol/l HCl, and
the extract was evaporated. The residue was reconstituted
in a solution containing 0.02 mol/l heptafluorobutyric acid,
0.01 mol/l ammonium sulphate and acetonitrile (ergo
mobile phase), and this was applied to a HPLC system
(Shimadzu, LC-10ADvp, Kyoto, Japan) equipped with a
C18 reversed phase column (Separon SGX C18, 150 x
3 mm). We monitored the emission signal at 385 nm upon
excitation at 335 nm. Synthetic PEN was used as a stand-
ard. The concentration of PEN was expressed in nmol/l.
The peak area reproducibility involving complete ana-
lytical procedure (including sample hydrolysis, drying,
reconstitution, and HPLC analysis) in actual samples
was 95.6 %. Reproducibility of the HPLC determination
itself was 98.8 %. Based on our PEN measurements, limit
of detection was 1.76 nmol/l and limit of quantitation
5.87 nmol/l.Fig. 1 Correlations between age and pentosidine levels in serum and bone
and osteoarthritis patients (empty circles, serum, r = 0.14, bone, r = 0.14), n.sData analyses and statistical methods
The sample size was estimated to enable detection of a
difference in PEN between the two groups of patients.
Results are expressed as percentages for categorical vari-
ables and as medians (95 % CI) or means (standard devi-
ation, S.D.) for continuous variables. Between-group
comparison of data was performed using the independ-
ent Student's t-test for continuous variables. A linear re-
gression method analyzing the relationship between two
variables was used; statistical significance of the correl-
ation was determined by Pearson coefficients. Multiple
linear regressions were used to estimate the differences
in serum and bone PEN between fracture and osteoarth-
ritis patients after adjusting for the effect of confounders
such as age, sex, weight, serum creatinine, and diabetes.
Values of p < 0.05 were considered significant. Statistical
analysis of data was performed using SigmaPlot 10 soft-
ware (Systat Software Inc, Germany).
Results
In osteoarthritis cases, a growing trend of serum and
bone PEN with age was found. In addition, a growing
trend of serum PEN with age was found in individuals
with fractures (Fig. 1). In fracture as well as in osteoarth-
ritis patients, no significant correlation was found be-
tween serum creatinine and serum or bone PEN. No
significant difference was found in PEN content in dry
bone (using paired samples) from the femoral head and
iliac crest. Serum 25-hydroxyvitamin D was measured in
46 fracture patients, concentrations < 25 nmol/l were
found in 22 % of them.
Serum and bone concentrations of PEN were signifi-
cantly higher in subjects with hip fractures compared
with osteoarthritis patients (Fig. 2). Significant differ-
ences in serum and bone PEN between fracture and
osteoarthritis patients remained even after adjustmentin patients with hip fracture (full circles, serum, r = 0.13, bone, r = 0.11)
. for all
Fig. 2 Pentosidine content in serum and bone in patients with hip fracture and in hip osteoarthritis patients
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0.001). A significant positive correlation was found between
bone and serum PEN in fracture patients (Fig. 3). Receiver
Operating Characteristics (ROC) curves indicated a compar-
able performance of serum and bone PEN in differentiation
between fracture cases and osteoarthritis patients (Fig. 4).
Discussion
Previous studies have demonstrated that histomorphometric
indices of trabecular bone micro-architecture were more fa-
vorable in patients undergoing arthroplasty for hip osteo-
arthritis than in patients with hip fracture, as well as in
comparison with age-matched subjects [22–25]. In this
study, bone PEN levels, considered surrogate markers of
quality of organic bone matrix, were measured to assess an-
other determinant of strength of bone, the bone tissue ma-
terial properties. To our knowledge, this is the first study
comparing serum and bone pentosidine levels in patients
with low-impact hip fractures and in patients with advanced
osteoarthritis. Our patients with hip fractures had higherFig. 3 Correlation between bone and serum pentosidine in
osteoarthritis patients (empty circles, dotted line, r = 0.11, n.s.) and in
fractured cases (full circles and line, r = 0.27, p < 0.05)serum and bone PEN concentrations than those with ad-
vanced stages of hip osteoarthritis. Previously, PEN content
in cortical and trabecular bone of patients with femoral neck
fractures has been shown to be higher than in those of age-
matched controls [18, 26]. However, the proof of the associ-
ation between the risk of hip fractures and serum and bone
PEN levels would require further studies, considering also
bone microarchitecture, bone mineral density (BMD), clin-
ical factors of risk of fracture and namely the general frailty
of hip fracture patients should be considered [27, 28].
The association between bone PEN and fracture risk ap-
pears independent of BMD mainly in type-I diabetes [29–
31]. Also, using an Enzyme-Linked ImmunoSorbent Assay
(ELISA), the association between serum PEN levels and
changes in BMD in patients treated with bisphosphonateFig. 4 Performance comparison of serum pentosidine, AUC = 0.906
(full line) and bone pentosidine, AUC = 0.845 (dotted line), p = 0.274.
AUC: area under the curve
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pausal women, only a moderate BMD-independent associ-
ation between urinary PEN and the incidence of vertebral
and non-vertebral fractures was observed [28, 33, 34]. In
the French OFELY study, there was a significant association
between urinary PEN and the risk of all fractures in 396
healthy postmenopausal women, although, the odds ratio
was not significant after adjustment for BMD [35].
This study has several limitations. First, the results in
our patients must be interpreted within the context of
differences in age and body weight, as well as the admit-
ted risk factors for hip osteoarthritis, hip osteoporosis
and fractures, although our results were adjusted for
age, sex, weight, serum creatinine, and diabetes. The in-
creasing trend in serum and bone PEN levels with age,
which were observed in this study, was in accordance
with that seen in other studies using HPLC [10], or
ELISA [5, 36, 37]. Second, for ethical reasons, bone PEN
levels in our patients were not compared with those in
healthy age matched subjects from the general popula-
tion. There was limited data on the differences between
PEN levels in osteoarthritis and in healthy subjects, ex-
cept for an observation that found no significant differ-
ences in plasma PEN levels in 17 patients with
osteoarthritis compared with controls [19]. Previously,
we reported that in patients with knee osteoarthritis,
PEN serum concentrations were increased compared
with healthy controls, and correlated with a cartilage de-
struction marker (cartilage oligomeric matrix protein) in
synovial fluid [38]. However, knee osteoarthritis is
mostly hypertrophic while in the majority of our pa-
tients, hip osteoarthritis was mostly of the atrophic type.
Thus, although the interpretation of serum PEN levels
in patients with knee and hip osteoarthritis and hip frac-
ture should be done with caution, pentosidine crosslink-
ing can nonetheless be considered as a measure of local
bone age. Accordingly, serum PEN levels were higher in
osteoporotic patients with long term aminobisphospho-
nate treatment than in BMD-matched controls [39].
Pentosidine formation is closely linked not only to glyca-
tion but also to oxidative processes [40, 41]. Accumula-
tion of advanced non-enzymatic glycation end products
in numerous body tissues during the course of aging, in
diabetes, and in rheumatoid arthritis has been associated
with oxidative stress [13]. It remains unknown whether
the increase in AGE modified proteins in patients with
chronic inflammation merely represents oxidative stress
or they actively participate in bone and joint destruction
[19]. Also, it is unclear to what extent serum PEN con-
tributes to bone strength at fractured sites, since bone
fractures are strain-controlled and PEN affects the or-
ganic matrix, which is better known as a contributor to
post-yield deformation of bone rather than to its elastic
properties [9]. Third, PEN has been shown to be alsosecreted from tissues other than bone and it is unclear
what proportion of serum PEN levels actually reflects
PEN content in bone. Compared with controls, PEN
levels are significantly increased not only in aging, osteo-
porosis, diabetes mellitus, renal disorders, and rheuma-
toid arthritis [4, 5, 42–45], but have also been reported
to correlate with the radiographic severity of lumbar
spondylosis without vertebral fractures [46]. Increased
serum PEN was an independent risk factor for loss of
muscle mass in postmenopausal women with type 2 dia-
betes [47]. Finally, BMD measurements or histomorpho-
metry of tetracycline labeled bone could not be
performed in our patients with incident hip fractures, or
those undergoing arthroplasty for hip osteoarthritis.
Serum markers such as type 1 collagen cross-linked C-
telopeptide (βCTX) and procollagen type I amino-
terminal propeptide (PINP) were not measured in our
patients, since both markers are strongly affected by in-
cident fractures. These markers reflect whole body rates
of bone resorption and bone formation rather than the
rates of remodeling at specific skeletal sites containing
different ratios of trabecular to cortical component, each
with its own metabolic rates [48].Conclusions
Serum pentosidine can be considered a potential bio-
marker for identification of subjects with impaired qual-
ity of organic bone matrix. However, more studies are
necessary to define the predictive value of serum PEN
concerning fractures and the efficacy and safety of bone-
active drugs in osteoporosis therapy.
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